Advanced glycation end products and diabetic retinopathy


Autoria(s): Chen, M; Curtis, T M; Stitt, A W
Data(s)

2013

Resumo

<p>Diabetic retinopathy (DR) has a complex pathogenesis which is impacted by a raft of systemic abnormalities and tissue-specific alterations occurring in response to the diabetes milieu. Many pathogenic processes play key roles in retinal damage in diabetic patients. One such pathway is the formation and accumulation of advanced glycation endproducts (AGEs) and advanced lipoxidation end products (ALEs) which are relevant modifications with roles in the initiation and progression of pathology. In this review, AGE/ALE formation in the diabetic retina is discussed alongside their impact on retinal cell function. In addition, various inhibitors of the AGE-RAGE system and their therapeutic utility for DR will also be evaluated.</p>

Identificador

http://pure.qub.ac.uk/portal/en/publications/advanced-glycation-end-products-and-diabetic-retinopathy(fd8b2184-c15d-4271-82a8-c7b14bd792f7).html

http://dx.doi.org/10.2174/09298673113209990025

Idioma(s)

eng

Direitos

info:eu-repo/semantics/restrictedAccess

Fonte

Chen , M , Curtis , T M & Stitt , A W 2013 , ' Advanced glycation end products and diabetic retinopathy ' Current medicinal chemistry , vol 20 , no. 26 , pp. 3234-40 . DOI: 10.2174/09298673113209990025

Palavras-Chave #Animals #Diabetic Retinopathy #Glycosylation #Glycosylation End Products, Advanced #Humans
Tipo

article